Clene Inc. (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. are advancing toward a New Drug Application submission for their lead asset CNM-Au8® in treating amyotrophic lateral sclerosis, with expectations set for the fourth quarter of 2025. The late clinical-stage biopharmaceutical company recently released second quarter 2025 financial results and provided updates on its clinical programs focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
CEO Rob Etherington emphasized the company's progress, stating that upcoming meetings with the FDA will focus on extensive survival data generated by CNM-Au8® in ALS patients. These meetings and biomarker analyses represent the final steps toward potential submission of an NDA under the accelerated approval pathway for ALS by the end of 2025. Etherington reaffirmed the company's commitment to the ALS community, noting their unwavering dedication to developing an impactful therapeutic agent for this devastating disease.
CNM-Au8® represents an investigational first-in-class therapy that improves central nervous system cells' survival and function through a mechanism targeting mitochondrial function and the NAD pathway while reducing oxidative stress. The therapy's potential approval could significantly impact the treatment landscape for ALS patients who currently have limited therapeutic options. For more information about the company's developments, visit https://www.Clene.com.
The advancement of CNM-Au8® through the regulatory process demonstrates the ongoing innovation in neurodegenerative disease treatment and highlights the importance of mitochondrial health in addressing conditions like ALS, Parkinson's disease, and multiple sclerosis. Investors and stakeholders can access the latest news and updates relating to CLNN through the company's newsroom at https://ibn.fm/CLNN.
